출판 : MarketsandMarkets（마켓츠앤마켓츠）출판년월 : 2022년07월
유전자 치료(Gene Therapy) 시장 : 벡터[비바이러스(올리고뉴클레오티드), 바이러스(레트로바이러스, 아데노 관련)], 적응증(암, 신경질환, 간질환, 듀첸느형 근이영양증), 도입 방법(생체내, 생체외), 지역별 – 2027년까지 세계 예측
Gene Therapy Market by Vectors (Non-viral(Oligonucleotides), Viral(Retroviral, Adeno-associated)), Indication (Cancer, Neurological, Hepatological Diseases, Duchenne Muscular Dystrophy), Delivery Method (In Vivo, Ex Vivo), Region – Global Forecast to 2027
| 페이지수 | 154 |
| 도표수 | 198 |
| 구성 | 영문조사보고서 |
| 가격 |
The global gene therapy market is valued at an estimated USD 7.3 billion in 2022 and is projected to reach USD 17.2 billion by 2027, at a CAGR of 18.6% during the forecast period. Factors such asrising cases of neurological diseases and cancer, growing gene therapy product approvals, and increasing investment in gene therapy related research and development drive the market growth.
전 세계 유전자 치료 시장은 2022년에 73억 달러로 추산되며 예측 기간 동안 18.6%의 CAGR로 2027년까지 172억 달러에 이를 것으로 예상됩니다. 신경계 질환 및 암 사례 발생, 유전자 치료 제품 승인 증가, 유전자 치료 관련 연구 및 개발에 대한 투자 증가와 같은 요인이 시장 성장을 주도합니다.
However,factors like high cost of gene therapy is restraining the growth of this market.
“The cancer segment accounted for the highest growth ratein the gene therapy market, by indication, during the forecast period”
In 2021, cancer segment accounted for the highest growth rate. Growing disease burden of cancer across the globe coupled with rising demand for gene therapies to treat cancer will augment the segmental growth of cancer over the forecast period.
“Asia Pacific: The fastest-growing region in the gene therapy market”
The Asia Pacific market is estimated to record the highest CAGR during the forecast period. The high growth rate of this market can be attributed to the improving healthcare expenditure in emerging economies, increasing product launches, and increasing incidence of cancer and neurological diseases.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1- 32%, Tier 2- 44%, and Tier 3-24%
• By Designation: C-level (Managers) – 30%, D-level(CXOs, Directors)- 34%, and Others (Executives) – 36%
• By Region: North America -50%, Europe -32%, Asia-Pacific -10%, Rest of the World -8%
List of Companies Profiled in the Report:
• Biogen (US)
• Sarepta Therapeutics (US)
• Gilead Sciences, Inc. (US)
• Amgen, Inc. (US)
• Novartis AG (Switzerland)
• Orchard Therapeutics Plc (UK)
• Spark Therapeutics, Inc. (A Part Of F. Hoffmann-La Roche) (US)
• AGC Biologics (US)
• Anges, Inc. (Japan)
• Bluebird Bio, Inc. (US)
• Jazz Pharmaceuticals Plc (Ireland)
• Dynavax Technologies (US)
• Human Stem Cells Institute (Russia)
• SibionoGenetech Co., Ltd. (China)
• Shanghai Sunway Biotech Co., Ltd. (China)
• Uniqure N.V. (Netherland)
• Gensight Biologics S.A. (France)
• Celgene Corporation (A Bristol-Myers Squibb Company) (US)
• Cellectis (France)
• Sangamo Therapeutics (US)
• Mustang Bio (US)
• AGTC (Applied Genetic Technologies Corporation) (US)
• Poseida Therapeutics, Inc. (US)
Research Coverage:
This report provides a detailed picture of the global gene therapy market. It aims at estimating the size and future growth potential of the market across different segments such as vectors, indication, delivery method, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, challenges,trends,and opportunities.
목차
TABLE OF CONTENTS
1 INTRODUCTION (Page No. – 23)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. – 26)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
FIGURE 2 KEY DATA FROM SECONDARY SOURCES
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 COMPANY REVENUE ANALYSIS
FIGURE 4 COMPANY REVENUE ANALYSIS
2.2.3 GROWTH FORECAST
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RISK ASSESSMENT
3 EXECUTIVE SUMMARY (Page No. – 32)
FIGURE 6 GENE THERAPY MARKET, BY VECTOR, 2022 VS. 2027 (USD MILLION)
FIGURE 7 GENE THERAPY MARKET, BY DELIVERY METHOD, 2022 VS. 2027 (USD MILLION)
FIGURE 8 GENE THERAPY MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 9 GENE THERAPY MARKET: REGIONAL SNAPSHOT
4 PREMIUM INSIGHTS (Page No. – 35)
4.1 GENE THERAPY MARKET OVERVIEW
FIGURE 10 HIGH INCIDENCE OF CANCER & OTHER TARGETED DISEASES TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR (2021)
FIGURE 11 NON-VIRAL VECTORS DOMINATE NORTH AMERICAN GENE THERAPY MARKET
4.3 GEOGRAPHICAL SNAPSHOT OF THE GENE THERAPY MARKET
FIGURE 12 APAC COUNTRIES TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. – 37)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 13 GENE THERAPY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 High incidence of cancer and other target diseases
TABLE 1 NUMBER OF NEW CANCER CASES, 2020 VS. 2025
5.2.1.2 Product approvals
TABLE 2 PRODUCT APPROVALS, 2015–2021
5.2.1.3 Funding for gene therapy research
5.2.2 OPPORTUNITIES
5.2.2.1 Strong product pipeline
TABLE 3 GENE THERAPY MARKET: INDICATIVE LIST OF PIPELINE DRUGS
5.2.3 CHALLENGES
5.2.3.1 High treatment costs
TABLE 4 PRICE OF GENE THERAPY PRODUCTS, 2021
5.3 PRICING ANALYSIS
5.4 TECHNOLOGY ANALYSIS
FIGURE 14 KEY STEPS IN GENE THERAPY
5.5 SUPPLY CHAIN ANALYSIS
5.5.1 PROMINENT COMPANIES
5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES (SMES)
5.5.3 END USERS
FIGURE 15 GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS OF GENE THERAPY MARKET
TABLE 5 STAKEHOLDERS IN THE GENE THERAPY ECOSYSTEM AND THEIR ROLES
5.7 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 6 GENE THERAPY MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.8 REGULATORY ANALYSIS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PORTER’S FIVE FORCES ANALYSIS
TABLE 11 GENE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
5.9.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 16 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GENE THERAPY PRODUCTS
5.10.2 BUYING CRITERIA FOR GENE THERAPY PRODUCTS
FIGURE 17 KEY BUYING CRITERIA FOR END USERS
6 GENE THERAPY MARKET, BY VECTOR (Page No. – 49)
6.1 INTRODUCTION
TABLE 12 GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
6.2 NON-VIRAL VECTORS
TABLE 13 GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
TABLE 14 GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
6.2.1 OLIGONUCLEOTIDES
6.2.1.1 Oligonucleotides account for the largest share of the non-viral vectors market
TABLE 15 GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION)
6.2.2 OTHER NON-VIRAL VECTORS
TABLE 16 GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
6.3 VIRAL VECTORS
TABLE 17 GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
TABLE 18 GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
6.3.1 RETROVIRAL VECTORS
TABLE 19 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
TABLE 20 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
6.3.1.1 Gamma-retroviral vectors
6.3.1.1.1 Availability of wide range of gamma-retroviral vectors supports market growth
TABLE 21 GENE THERAPY MARKET FOR GAMMA-RETROVIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
6.3.1.2 Lentiviral vectors
6.3.1.2.1 North America to dominate lentiviral vectors market
TABLE 22 GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
6.3.2 ADENO-ASSOCIATED VIRUS VECTORS
6.3.2.1 Potential applications in in vivo applications to drive interest in AAV vectors
TABLE 23 GENE THERAPY MARKET FOR AAV VECTORS, BY REGION, 2020–2027 (USD MILLION)
6.3.3 OTHER VIRAL VECTORS
TABLE 24 GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION)
7 GENE THERAPY MARKET, BY INDICATION (Page No. – 56)
7.1 INTRODUCTION
TABLE 25 GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
7.2 NEUROLOGICAL DISEASES
7.2.1 NEUROLOGICAL DISEASES TO FORM THE LARGEST INDICATION SEGMENT IN THIS MARKET
TABLE 26 GENE THERAPY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2020–2027 (USD MILLION)
7.3 CANCER
7.3.1 GROWING DEMAND FOR CANCER THERAPIES TO DRIVE MARKET GROWTH
TABLE 27 NUMBER OF NEW CANCER CASES, BY TYPE, 2020–2040
TABLE 28 GENE THERAPY MARKET FOR CANCER, BY REGION, 2020–2027 (USD MILLION)
7.4 DUCHENNE MUSCULAR DYSTROPHY
7.4.1 RISING PREVALENCE OF DMD TO SUPPORT MARKET GROWTH
TABLE 29 GENE THERAPY MARKET FOR DMD, BY REGION, 2020–2027 (USD MILLION)
7.5 HEPATOLOGICAL DISEASES
7.5.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS TO SUPPORT MARKET GROWTH
TABLE 30 GENE THERAPY MARKET FOR HEPATOLOGICAL DISEASES, BY REGION, 2020–2027 (USD MILLION)
7.6 OTHER INDICATIONS
TABLE 31 GENE THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2020–2027 (USD MILLION)
8 GENE THERAPY MARKET, BY DELIVERY METHOD (Page No. – 62)
8.1 INTRODUCTION
TABLE 32 GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
8.2 IN VIVO GENE THERAPY
8.2.1 IN VIVO GENE THERAPY TO DOMINATE MARKET
TABLE 33 IN VIVO GENE THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION)
8.3 EX VIVO GENE THERAPY
8.3.1 EX VIVO GENE THERAPY SEGMENT TO WITNESS HIGH GROWTH
TABLE 34 EX VIVO GENE THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION)
9 GENE THERAPY MARKET, BY REGION (Page No. – 65)
9.1 INTRODUCTION
TABLE 35 GENE THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 18 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT
TABLE 36 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 38 NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 40 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 41 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 42 NORTH AMERICA: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.2.1 US
9.2.1.1 US dominates the global gene therapy market
TABLE 43 LIST OF GENE THERAPY PIPELINE CANDIDATES OF US-BASED COMPANIES
TABLE 44 US FDA GENE THERAPY PRODUCT APPROVALS
TABLE 45 US: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 46 US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 47 US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 48 US: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 49 US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 50 US: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Growing burden of cancer supports market growth in Canada
TABLE 51 CANADA: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 52 CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 53 CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 54 CANADA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 55 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 56 CANADA: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.3 EUROPE
TABLE 57 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 58 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 59 EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 60 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 61 EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 62 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 63 EUROPE: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Germany dominates European gene therapy market
TABLE 64 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 65 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 66 GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 68 GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 69 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 70 GERMANY: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.3.2 FRANCE
9.3.2.1 Increasing cancer incidence to support market growth
TABLE 71 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 72 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 73 FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 74 FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 77 FRANCE: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.3.3 UK
9.3.3.1 Rising incidence of melanoma to support market growth in UK
TABLE 78 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 79 UK: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 80 UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 81 UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 82 UK: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 83 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 84 UK: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.3.4 ITALY
9.3.4.1 High incidence of targeted diseases and increasing healthcare spending to drive Italian market growth
TABLE 85 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 86 ITALY: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 87 ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 88 ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 89 ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 90 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 91 ITALY: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Rising cancer incidence and increasing healthcare expenditure to support market growth in Spain
TABLE 92 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 93 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 94 SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 95 SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 98 SPAIN: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 99 ROE: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 100 ROE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 101 ROE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 102 ROE: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 ROE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 104 ROE: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 19 ASIA PACIFIC: GENE THERAPY MARKET SNAPSHOT
TABLE 105 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 106 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 107 ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 108 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 110 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 111 ASIA PACIFIC: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.4.1 JAPAN
9.4.1.1 Japan dominates the APAC gene therapy market
TABLE 112 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 113 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 114 JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 115 JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 116 JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 118 JAPAN: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.4.2 CHINA
9.4.2.1 Rising prevalence of cancer and established base for gene therapy to support market growth in China
TABLE 119 CHINA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
TABLE 120 CHINA: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 121 CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 123 CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 124 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 125 CHINA: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.4.3 REST OF ASIA PACIFIC
TABLE 126 ROAPAC: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 127 ROAPAC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 128 ROAPAC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 129 ROAPAC: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 130 ROAPAC: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 131 ROAPAC: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
9.5 REST OF THE WORLD
TABLE 132 ROW: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION)
TABLE 133 ROW: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 134 ROW: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION)
TABLE 135 ROW: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 136 ROW: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 ROW: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. – 102)
10.1 OVERVIEW
FIGURE 20 KEY DEVELOPMENTS IN THE GENE THERAPY MARKET
10.2 MARKET SHARE ANALYSIS, 2021
FIGURE 21 GENE THERAPY MARKET SHARE ANALYSIS, 2021
TABLE 138 GENE THERAPY MARKET: DEGREE OF COMPETITION
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 22 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN GENE THERAPY, 2019–2021
10.4 COMPANY EVALUATION QUADRANT
10.4.1 STARS
10.4.2 EMERGING LEADERS
10.4.3 PERVASIVE PLAYERS
10.4.4 PARTICIPANTS
FIGURE 23 GENE THERAPY MARKET: COMPANY EVALUATION QUADRANT, 2021
10.5 COMPANY FOOTPRINT ANALYSIS
10.5.1 PRODUCT FOOTPRINT OF COMPANIES
TABLE 139 GENE THERAPY MARKET: COMPANY PRODUCT FOOTPRINT (2021) ACROSS INDICATIONS
10.6 COMPETITIVE SCENARIO
TABLE 140 PRODUCT APPROVALS, 2018–2022
TABLE 141 DEALS, 2018–2022
TABLE 142 OTHER DEVELOPMENTS, 2018-2022
11 COMPANY PROFILES (Page No. – 110)
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1 BIOGEN
TABLE 143 BIOGEN: BUSINESS OVERVIEW
FIGURE 24 BIOGEN: COMPANY SNAPSHOT
11.2 SAREPTA THERAPEUTICS
TABLE 144 SAREPTA THERAPEUTICS: BUSINESS OVERVIEW
FIGURE 25 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT
11.3 GILEAD SCIENCES, INC.
TABLE 145 GILEAD SCIENCES INC: BUSINESS OVERVIEW
FIGURE 26 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
11.4 AMGEN, INC.
TABLE 146 AMGEN INC: BUSINESS OVERVIEW
FIGURE 27 AMGEN, INC.: COMPANY SNAPSHOT
11.5 NOVARTIS AG
TABLE 147 NOVARTIS AG: BUSINESS OVERVIEW
FIGURE 28 NOVARTIS AG: COMPANY SNAPSHOT
11.6 ORCHARD THERAPEUTICS PLC
TABLE 148 ORCHARD THERAPEUTICS PLC: BUSINESS OVERVIEW
FIGURE 29 ORCHARD THERAPEUTICS PLC: COMPANY SNAPSHOT
11.7 SPARK THERAPEUTICS, INC. (AN F. HOFFMANN-LA ROCHE COMPANY)
TABLE 149 SPARK THERAPEUTICS INC: BUSINESS OVERVIEW
11.8 AGC BIOLOGICS
TABLE 150 AGC BIOLOGICS: BUSINESS OVERVIEW
11.9 ANGES, INC.
TABLE 151 ANGES INC: BUSINESS OVERVIEW
FIGURE 30 ANGES, INC.: COMPANY SNAPSHOT
11.1 BLUEBIRD BIO, INC.
TABLE 152 BLUEBIRD BIO: BUSINESS OVERVIEW
FIGURE 31 BLUEBIRD BIO: COMPANY SNAPSHOT
11.11 JAZZ PHARMACEUTICALS PLC
TABLE 153 JAZZ PHARMACEUTICALS: BUSINESS OVERVIEW
FIGURE 32 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT
11.12 DYNAVAX TECHNOLOGIES
TABLE 154 DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 33 DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT
11.13 HUMAN STEM CELLS INSTITUTE
TABLE 155 HUMAN STEM CELLS INSTITUTE: BUSINESS OVERVIEW
11.14 SIBIONO GENETECH CO., LTD.
TABLE 156 SIBIONO GENETECH CO LTD: BUSINESS OVERVIEW
11.15 SHANGHAI SUNWAY BIOTECH CO., LTD.
TABLE 157 SHANGHAI SUNWAY BIOTECH CO LTD: BUSINESS OVERVIEW
11.16 UNIQURE N.V.
TABLE 158 UNIQURE NV: BUSINESS OVERVIEW
11.17 GENSIGHT BIOLOGICS S.A.
TABLE 159 GENSIGHT BIOLOGICS SA: BUSINESS OVERVIEW
11.18 CELGENE CORPORATION (A BRISTOL-MYERS SQUIBB COMPANY)
TABLE 160 CELGENE CORPORATION: BUSINESS OVERVIEW
11.19 CELLECTIS
TABLE 161 CELLECTIS: BUSINESS OVERVIEW
11.2 SANGAMO THERAPEUTICS
TABLE 162 SANGAMO THERAPEUTICS: BUSINESS OVERVIEW
11.21 MUSTANG BIO
TABLE 163 MUSTANG BIO: BUSINESS OVERVIEW
11.22 AGTC (APPLIED GENETIC TECHNOLOGIES CORPORATION)
TABLE 164 AGTC: BUSINESS OVERVIEW
11.23 POSEIDA THERAPEUTICS, INC.
TABLE 165 POSEIDA THERAPEUTICS INC: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12 APPENDIX (Page No. – 153)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
